

## Supplemental Information


### Macrocyclic oxygen transfer in conversion of fatty acid hydroperoxide to a single species of triol in physiological saline

Min Suk Choi, William E. Boeglin, Donald F. Stec, M. Wade Calcutt, Ned A. Porter and Alan R. Brash

#### Supplemental text: $\alpha$ -Tocopherol-controlled autoxidation of 17S-HPDHA, **1**

The assigned structure of (Neuro)Protectin D1 (PD1 or NPD1), (Scheme S1), has been challenged over the years based on its original characterization as a product of soybean lipoxygenase activity (which goes against precedent) and close co-chromatography of synthetic PD1 with several other dihydroxy isomers of DHA.<sup>1-4</sup> To examine its potential non-enzymic formation from 17S-HPDHA (**1**), we initiated a study of the  $\alpha$ -tocopherol-controlled autoxidation of **1**, along the lines of other polyunsaturated fatty acid substrates,<sup>5-7</sup> specifically to examine the potential formation of (neuro)protectin D1, a 10*R*,17*S* diol and structural analogue of leukotriene B<sub>4</sub>, Scheme S1,<sup>8</sup> 17S-HPDHA **1** (1 mg) was mixed with  $\alpha$ -tocopherol (50 % by weight) and incubated overnight at room temperature as the neat oil.  $\alpha$ -Tocopherol (vitamin E) acts as a radical trap of the initially-formed fatty acid peroxy radicals as hydroperoxides.<sup>5</sup> The UV spectrum of the reaction indicated an approximately 25% decrease in the 237 nm conjugated diene chromophore of the starting material with a corresponding increase in absorbance around 270 nm. The sample was reduced with NaBH<sub>4</sub> and analyzed by RP- and NP-HPLC, separating pairs of diastereomers of 10,17-dihydroxy derivatives with all-*trans* or *trans,cis,trans* conjugated trienes as expected from vitamin E-controlled autoxidation of other polyunsaturated fatty acid hydroperoxides.<sup>6,7</sup> To examine the potential formation of a 10,17-dihydroxy derivative with *trans,trans,cis* conjugated triene (i.e. matching Protectin D1<sup>8-10</sup>), synthetic PD1 was chromatographed with aliquots of the reduced reaction products. On RP-HPLC, PD1 co-chromatographs with other 10,17-dihydroxy isomers and is not clearly distinguished other than by advanced LC-MS methodologies (c.f.<sup>4,11</sup>). However, on NP-HPLC PD1 is clearly resolved from other isomers and was found to be absent from the 17-HPDHA autoxidation (Supplement, Figure S1). Further analyses were not conducted and we switched to examining the fate of 17-HPDHA upon incubation in phosphate-buffered saline (PBS).

Supplementary Scheme S1



#### Supplemental Figure S1:

##### NP-HPLC of NaBH<sub>4</sub>-reduced autoxidation products of 17S-HPDHA (with added PD1)

Figure S2: Proton NMR spectrum and COSY analysis of synthetic 4,5-epoxy-17-hydroxy-22:5 $\omega$ 3 as the methyl ester in d<sub>6</sub>-benzene

Figure S3: Proton NMR spectrum and COSY analysis of synthetic 4,5-epoxy-17-hydroxy-22:5 $\omega$ 3 as the free acid in d<sub>6</sub>-benzene

#### Supplemental Figure S4

RP-HPLC of  $\gamma$ -lactone of 4,5,17-trihydroxy-22:5 $\omega$ 3 control and after 5 days in PBS at 37 °C

#### Supplemental Figure S5:

RP-HPLC of 4,5-*cis*-epoxy-5,17-dihydroxy-22:5 $\omega$ 3 after incubation overnight in PBS

**Supplemental Figure S1:**

**NP-HPLC of NaBH<sub>4</sub>-reduced autoxidation products of 17S-HPDHA (with added PD1)**

Aliquots of an autoxidation of 17S-HPDHA were reduced with NaBH<sub>4</sub> and chromatographed on an Agilent 1100 series instrument with an Avantor silica 5 μ HPLC column, a solvent system of hexane/isopropanol/glacial acetic acid (100:3:0.02 by volume), a flow rate of 2 ml/min with diode array UV detection with the 270 nm channel recording illustrated.


A: NaBH<sub>4</sub>-reduced autoxidation products

B: Another aliquot chromatographed with added synthetic PD1


Avantor 5 μ Silica column (25 x 0.46 cm)  
Solvent: hexane/IPA/HAc (100:3:0.02)  
Flow rate: 2 ml/min  
Detection: Diode array, 270 nm channel

10,17-Diols  
with *trans-cis-trans*  
conjugated triene

A




B



**Supplemental Figure S2**

**Proton NMR spectrum and COSY analysis of synthetic 4,5-epoxy-17-hydroxy-22:5 $\omega$ 3 as the methyl ester in  $d_6$ -benzene**

The spectrum and COSY were recorded on the first eluting diastereomer from NP-HPLC




<sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>), Chemical shift, number of protons, multiplicity, *J*, and proton number:  $\delta$  (ppm), 6.71 (1H, dd, *J* = 15, 11 Hz, H15); 6.05 (1H, t, *J* = 10.9 Hz, H14); 5.69 (1H, dd, *J* = 15.1, 5.8 Hz, H16); 5.34 – 5.53 (7H, m, H7, H8, H10, H11, H13, H19, H20); 4.12 (1H, m, H17); 3.31 (3H, s, OCH<sub>3</sub>); 2.93 (2H, m, H12); 2.66 – 2.81 (4H, m, H4, H5, H9); 2.35 – 2.16 (5H, m, H2ab, H6b, H18); 2.06 (1H, m, H6a); 1.97 (2H, quintet, *J* = 7 Hz, H21); 1.81 (0.9H, d, -OH on C17); 1.76 - 1.63 (2H, m, 3a, 3b); 0.88 (3H, t, *J* = 7 Hz, H22).

**Supplemental Figure S3**

**Proton NMR spectrum and COSY analysis of synthetic 4,5-epoxy-17-hydroxy-22:5 $\omega$ 3 as the free acid in  $d_6$ -benzene**

The spectrum and COSY were recorded after KOH hydrolysis of the methyl ester derivative, extraction on an Oasis (Waters) cartridge without acidification, elution with ethyl acetate, NP-HPLC purification, and recording here of the first-eluting diastereomer.




$^1H$ -NMR (600 MHz,  $C_6D_6$ ), Chemical shift, number of protons, multiplicity,  $J$ , and proton number:  $\delta$  (ppm), 6.79 (1H, dd,  $J = 15.2, 11$  Hz, H15); 6.02 (1H, t,  $J = 11$  Hz, H14); 5.54 (1H, dd,  $J = 15.2, 5.2$  Hz, H16); 5.36 – 5.51 (5H, m, H8, H10, H11, H13, H20); 5.30 (2H, m, H7, H19); 4.08 (1H, q,  $J = 5.9$  Hz, H17); 3.04 (1H, m, H12a); 2.97 (1H, m, H12b); 2.07 – 2.22 (4H, m, H2a, H3a, H6); 2.22 – 2.07 (6H, m, H2b, H3b, H9, H18); 1.91 (2H, quintet,  $J = 7$  Hz, H21) 0.85 (3H, t,  $J = 7$  Hz, H22).

### Supplemental Figure S4

#### RP-HPLC of $\gamma$ -lactone of 4,5,17-trihydroxy-22:5 $\omega$ 3 control and after 5 days in PBS at 37 °C

A: As a control, the  $\gamma$ -lactone of 4,5,17-trihydroxy-22:5 $\omega$ 3 (5  $\mu$ g) was added to PBS at room temperature and extracted using an Oasis cartridge (without acidification), eluted with EtOAc, and an aliquot analyzed by RP-HPLC.

B: The  $\gamma$ -lactone of 4,5,17-trihydroxy-22:5 $\omega$ 3 (5  $\mu$ g) was incubated for 5 days in PBS at 37 °C, then extracted and analyzed as above. The analyses used a Waters 5 $\mu$  Symmetry column (25 x 0.46 cm) with a solvent of acetonitrile/water/glacial acetic acid (45:55:0.01 by volume) at a flow rate of 1 ml/min, with diode array detection at 205, 220, 235 and 270 nm wavelengths.




### Supplemental Figure S5:

#### RP-HPLC of 4,5-*cis*-epoxy-5,17-dihydroxy-22:5 $\omega$ 3 after incubation overnight in PBS

Synthetic 4,5-epoxy-5,17-diol (10  $\mu$ g) was incubated overnight in PBS at 37 °C, extracted using an Oasis cartridge (without acidification), eluted with EtOAc, and an aliquot analyzed by RP-HPLC using a Waters 5 $\mu$  Symmetry column (25 x 0.46 cm) with a solvent of acetonitrile/water/glacial acetic acid (45:55:0.01 by volume) at a flow rate of 1 ml/min, with diode array detection at 205, 220, 235 and 270 nm wavelengths. There was no detectable hydrolysis to the corresponding  $\gamma$ -lactone derivative.

#### RP-HPLC after overnight incubation in PBS at 37 deg C



#### References

1. I. A. Butovich, J. Lipid Res., 2005, 46, 2311–2314.
2. L. Balas, M. Guichardant, T. Durand and M. Lagarde, Biochimie, 2014, 99, 1–7.
3. J. Jin, W. E. Boeglin and A. R. Brash, J. Lipid Res., 2021, 62.
4. N. Kampschulte, R. Kirchhoff, A. Löwen and N. H. Schebb, J. Lipid Res., 2024, 65, ARTN 100694.
5. K. E. Peers and D. T. Coxon, Chem. Phys. Lipids, 1983, 32, 49–56.
6. D. T. Coxon, K. E. Peers and N. M. Rigby, J. Chem. Soc. Chem. Commun., 1984, <https://doi.org/DOI.10.1039/c3984000006767-68>.
7. C. L. Rector, D. F. Stec, A. R. Brash and N. A. Porter, Chemical research in toxicology, 2007, 20, 1582–1593.
8. C. N. Serhan and N. A. Petasis, Chem. Rev., 2011, 111, 5922–5943.
9. C. N. Serhan and B. D. Levy, J. Clin. Invest., 2018, 128, 2657–2669.
10. T. V. Hansen and C. N. Serhan, Biochem. Pharmacol., 2022, 206, ARTN 115330.
11. L. Kutzner, K. M. Rund, A. I. Ostermann, N. M. Hartung, J. M. Galano, L. Balas, T. Durand, M. S. Balzer, S. David and N. H. Schebb, Front. Pharmacol., 2019, 10, ARTN 169.